Jci_page_head_homepage_01 Jci_page_head_homepage_02
Eiki Takimoto, Norimichi Koitabashi, Steven Hsu, Elizabeth A. Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L. Gabrielson, Robert Blanton, David P. Siderovski, Michael E. Mendelsohn, David A. Kass
Published in Volume 119, Issue 2
J Clin Invest. 2009; 119(2):408–420 doi:10.1172/JCI35620
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4
Gαq as a critical target of RGS2.

(A) Inhibition of PLCβ with U73122 prevents exacerbated hypertrophy (heart weight/tibia length), chamber dilation, and dysfunction (n = 7–14 per group). *P < 0.001 versus other groups. (B) In Rgs2–/– mice subjected to 48 h TAC, the inactive control agent U73343 did not suppress pathological remodeling. Summary echo data are provided in Supplemental Figure 2B. (C) Cardiac hypertrophy was exacerbated in double-mutant Gαq-OE+Rgs2–/– mice (n = 7–9 per group). **P < 0.01 versus other groups. (D) Corresponding echocardiograms showed worsened function and chamber dilation. (E) Summary data for LV diastolic dimension, FS, and heart rate (n = 7–9 per group). *P < 0.05 versus other groups; P < 0.05 versus all Gαq-OE groups. (F) Response of cardiac LV mass and echocardiographic FS in mice subjected to swimming versus sedentary animals. Exercise-induced hypertrophy was similar in Rgs2+/+ and Rgs2–/– mice, with no change in FS. *P < 0.01, P < 0.05 versus respective week-0 baseline.